A Clinical Diagnostic System for Intrinsic Acute Kidney Disease
NCT ID: NCT06606522
Last Updated: 2024-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1360 participants
OBSERVATIONAL
2024-06-01
2024-09-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Can a clinical model comprised of common clinical indexes help diagnose AKD ?
2. Can a combinition of several urinary biomarkers help diagnose AKD ? The study will be conducted in retrospective cohorts of patients with AKD undergoing kidney biopsy. The gold standard of the study is histological diagnosis of AKD. The model will be developed in a derivation cohort from one center, and will be further externally validated in a multicent cohort. The urinary biomarkers will only be tested in the derivation cohort.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development and Validation of a Real-time Prediction Model for Acute Kidney Injury in Hospitalized Patients
NCT06597838
Early Prediction of Acute Kidney Injury in High Risk Patients After Non-cardiac Surgery
NCT03880110
Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy
NCT03658317
Etiology, Epidemiology and Prognostics of Acute Kidney Injury (AKI)
NCT00953992
Novel Biomarkers and Postoperative Kidney Injury in Radical Nephrectomy
NCT07088874
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Derivation cohort
Patients from Peking University First Hospital
Clinical model
Clinical model: a clinical model based on basic demorgraphic information and commonly executed laboratory tests to differentiate different pathological types of intrinsic AKD.
Urinary biomarkers
Urinary biomarkers: biomarkers help differentiate different pathological types of intrinsic AKD.
External Validation Cohort
Patients from other four centers
Clinical model
Clinical model: a clinical model based on basic demorgraphic information and commonly executed laboratory tests to differentiate different pathological types of intrinsic AKD.
Urinary biomarkers
Urinary biomarkers: biomarkers help differentiate different pathological types of intrinsic AKD.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clinical model
Clinical model: a clinical model based on basic demorgraphic information and commonly executed laboratory tests to differentiate different pathological types of intrinsic AKD.
Urinary biomarkers
Urinary biomarkers: biomarkers help differentiate different pathological types of intrinsic AKD.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1. underwent a biopsy to evaluate renal allograft rejection;
2. had a history of hematopoietic stem cell transplantation;
3. were diagnosed with hematological malignancy or end-stage tumor with kidney metastasis;
4. were tested antineutrophil cytoplasmic autoantibody (ANCA) or double-strand DNA (dsDNA) or anti-glomerular basement membrane (GBM) antibody positive before biopsy.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Affiliated Hospital of Hebei University
OTHER
Beijing Miyun Hospital
UNKNOWN
Dongzhimen Hospital, Beijing
OTHER
Taiyuan Central Hospital of Shanxi Medical University
OTHER
Peking University First Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Li Yang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Li Yang, Professor
Role: PRINCIPAL_INVESTIGATOR
Peking University First Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dongzhimen Hospital of Beijing University of Chinese Medicine
Beijing, Beijing Municipality, China
Peking University First Hospital
Beijing, Beijing Municipality, China
Beijing Miyun District Hospital
Beijing, Beijing Municipality, China
Affliated Hospital of Hebei University
Baoding, Hebei, China
Taiyuan Central Hospital
Taiyuan, Shanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-379-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.